Smart Materials Medtech Company Strengthens Board as Lead Products Approach Clinic LONDON, October 27
LONDON, October 27 /PRNewswire/ -- UK medical technology company
BioCeramic Therapeutics Ltd is delighted to announce that Sir Richard Sykes
has accepted the role of Chairman of its Board of Directors. Sir Richard,
former Chairman of pharmaceuticals company GlaxoSmithKline plc, takes up the
post with immediate effect.
BioCeramic Therapeutics Ltd is a spinout from Imperial College in London,
where Sir Richard was Rector until earlier this year.
BCT is a pioneer in the exciting new field of regenerative medicine,
bringing together some of the world's best materials scientists doctors,
biologists and chemists in both private and public sectors. BCT is developing
two families of implants designed to promote tissue regeneration. Initial
applications are in orthopaedics and oral care, with plans to extend this to
a wide range of other tissues important in human diseases.
Daniel Green, BCT's CEO, said: "Sir Richard's immense experience and
expert guidance will be invaluable as we move to the next stage of our growth
plan: taking our lead development products to a stage where they benefit the
public."
About BioCeramic Therapeutics Ltd
BioCeramic Therapeutics Ltd is a regenerative medicine company.
Regenerative medicine's goal is to promote the body's natural tissue
regeneration capabilities. We have proprietary biologically active materials
that can be implanted or incorporated into other products. Initial markets
are orthopedics and oral care, and our goal is to be able to regenerate many
tissue types.
The underlying science is based on the work of Professor Molly Stevens,
Research Director for Biomedical Material Sciences in the Institute for
Biomedical Engineering and the Department of Materials at Imperial College,
London and Prof Robert Hill and Dr Julian Jones, of the Department of
Materials at Imperial College.
Based on their work, BCT is developing two generations of products. The
first generation (BCT-000 series) is a series of modified bioactive glasses.
The glasses incorporate carefully controlled amounts of strontium and other
ingredients. Their role is to promote tissue growth, ensure resorption over
time and inhibit pathogens. In addition, the right formulations enable their
deployment as filler materials, bioactive coatings, or as flexible and tough
rods and blocks with structural strength. These effects can be tailored to
applications in each of our target markets to deliver decisive advantages
over our competitors' products.
The second generation is a series of materials (BCT-100 series) is
structured on a nano-scale to mimic the extracellular matrix. This generation
moves beyond the capabilities of bioactive ceramics to address vastly larger
markets in soft tissue repair. This programme has been awarded substantial
grant-aid whose goal is an in vivo proof of principle.
http://www.bioceramictherapeutics.com
SOURCE BioCeramic Therapeutics Ltd
